How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis

PLoS Neglected Tropical Diseases

Volumn 11, Issue 9, 2017, Pages

  Kastner, Randee J ^a,b   Sicuri, Elisa ^c   Stone, Christopher M ^a,b,f   Matwale, Gabriel ^d   Onapa, Ambrose ^e   Tediosi, Fabrizio ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d MINISTRY OF HEALTH   (Uganda)

^e RTI INTERNATIONAL   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; EPIRUBICIN; IVERMECTIN; ANTIFILARIAL AGENT;

ARTICLE; BUDGET; CONSULTATION; COST CONTROL; DISEASE ERADICATION; DRUG ADMINISTRATION; DRUG COST; DRUG DISTRIBUTION; DRUG SENSITIZATION; DRUG SURVEILLANCE PROGRAM; ENDEMIC DISEASE; HEALTH CARE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; INVESTMENT; LYMPHATIC FILARIASIS; MOBILIZATION; NONHUMAN; PREVALENCE; PROGRAM COST EFFECTIVENESS; SCALE UP; TREATMENT DURATION; UGANDA; DISEASE TRANSMISSION; ECONOMIC MODEL; ECONOMICS; ELEPHANTIASIS, FILARIAL; PREVENTION AND CONTROL;

DISEASE ERADICATION; DISEASE TRANSMISSION, INFECTIOUS; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS; MODELS, ECONOMIC;

EID: 85030714691     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005934     Document Type: Article

References (58)

1. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. The New England journal of medicine. 2007;357(10):1018–27. doi: 10.1056/NEJMra064142 17804846.
2. Pham HV, Doan HT, Phan TT, Minh NN, Ecological factors associated with dengue fever in a Central Highlands province, Vietnam. BMC infectious diseases. 2011;11:172. doi: 10.1186/1471-2334-11-172 21679398.
3. World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases. summary. 2013.
4. Imperial College London. Schistosomiasis Control Initiative: What are Neglected Tropical Diseases (NTDs). http://www3.imperial.ac.uk/schisto/whatwedo/whatarentds.
5. Miguel E, Kremer M, Worms: Identifying Impacts on Education and Health in the Presence of Treatment Externalities. Econometrica. 2004;72(1):159–217. doi: 10.1111/j.1468-0262.2004.00481.x
6. World Health Organization. Lymphatic Filariasis. 2012;Fact Sheet(102).
7. Ottesen EA, Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol. 2006;61:395–441. doi: 10.1016/S0065-308X(05)61010-X 16735170.
8. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–223. doi: 10.1016/S0140-6736(12)61689-4 23245608.
9. Ton TG, Mackenzie C, Molyneux DH, The burden of mental health in lymphatic filariasis. Infectious diseases of poverty. 2015;4:34. doi: 10.1186/s40249-015-0068-7 26229599.
10. Hairston NG, de Meillon B, On the inefficiency of transmission of Wuchereria bancrofti from mosquito to human host. Bulletin of the World Health Organization. 1968;38(6):935–41. 4235739.
11. Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep. 1993;42(RR-16):1–38. 8145708.
12. Mak JW, Yen PK, Lim KC, Ramiah N, Zoonotic implications of cats and dogs in filarial transmission in Peninsular Malaysia. Trop Geogr Med. 1980;32(3):259–64. 7210162.
13. Preventive Chemotherapy Databank Lymphatic Filariasis [Internet]. WHO. 2015 [cited 2015 January 20]. http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/.
14. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease Control Priorities in Developing Countries: World Bank Publications; 2006.
15. Tediosi F, Steinmann P, de Savigny D, Tanner M, Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges. PLoS Negl Trop Dis. 2013;7(11):e2446. doi: 10.1371/journal.pntd.0002446 24244762.
16. Miller M, Barrett S, Henderson DA, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Control and Eradication. In: et al., editors. Disease Control Priorities in Developing Countries. 2nd ed. Washington (DC)2006.
17. Bailey TC, Merritt MW, Tediosi F, Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis. Am J Public Health. 2015;105(4):629–36. doi: 10.2105/AJPH.2014.302454 25713967.
18. Walker DG, Lupp J. Guide for preparing an eradication investment case. 2011.
19. Kastner RJ, Stone CM, Steinmann P, Tanner M, Tediosi F, What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs. PLoS Neglected Tropical Diseases. 2015;9(10):e0004147. doi: 10.1371/journal.pntd.0004147 26451729
20. Norman RA, Chan MS, Srividya A, Pani SP, Ramaiah KD, Vanamail P, et al. EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiology and infection. 2000;124(3):529–41. 10982078.
21. Clement Nee Shrive FM, Ghali WA, Donaldson C, Manns BJ, The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. Health Econ. 2009;18(4):377–88. doi: 10.1002/hec.1363 18615835.
22. CHOosing Interventions that are Cost Effective (WHO-CHOICE) [Internet]. World Health Organization.
23. WHO. African Programme for Onchocerciasis Control (APOC)30 July 2015. http://www.who.int/blindness/partnerships/APOC/en/.
24. Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP, Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am J Trop Med Hyg. 1998;58(4):461–9. 9574793.
25. Chippaux JP, Boussinesq M, Gardon J, Gardon-Wendel N, Ernould JC, Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas. Parasitol Today. 1996;12(11):448–50. 15275280.
26. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18–22. doi: 10.1016/S0140-6736(96)11094-1 9217715.
27. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, Yoon IK, Kalayanarooj S, Thipayamongkolgul M, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010. BMC public health. 2015;15:250. Epub 2015/04/18. doi: 10.1186/s12889-015-1590-z 25886528.
28. Zoure HG, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis. 2011;5(6):e1210. doi: 10.1371/journal.pntd.0001210 21738809.
29. Country TablesThe Little Green Data Book2015. p. 17–232.
30. Price level ratio of PPP conversion factor (GDP) to market exchange rate [Internet]. 2014.
31. Drummond F, Methods for the Economic Evaluation of Health Care Programmes: Oxford University Press; 2005.
32. Philip E Coyne DWB. The Mectizan (ivermectin) donation program for river blindness as a paradigm for pharmaceutical industry donation programs31 January 2015. http://apps.who.int/medicinedocs/documents/s17517en/s17517en.pdf
33. Michael E, Meyrowitsch DW, Simonsen PE, Cost and cost effectiveness of mass diethylcarbamazine chemotherapy for the control of bancroftian filariasis: comparison of four strategies in Tanzania. Trop Med Int Health. 1996;1(4):414–26. 8765447.
34. Goldman AS, Guisinger VH, Aikins M, Amarillo ML, Belizario VY, Garshong B, et al. National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl Trop Dis. 2007;1(1):e67. doi: 10.1371/journal.pntd.0000067 17989784.
35. World Bank World Development Indicators Online [Internet]. http://publications.worldbank.org/WDI/.
36. Amazigo U, Community selection of ivermectin distributors. Community Eye Health. 1999;12(31):39–40. 17491996.
37. McFarland D. Study of Cost Per Treatment with Ivermectin using the CDTI Strategy. 2005.
38. Briggs A, C K, Sculpher M, Decision modelling for health economic evaluation. Oxford, editor: Oxford University Press; 2003.
39. Keating J, Yukich JO, Mollenkopf S, Tediosi F, Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review. Acta Trop. 2014;135:86–95. doi: 10.1016/j.actatropica.2014.03.017 24699086.
40. John TJ, Who benefits from global certification of polio eradication?Indian J Med Res. 2004;120(5):431–3. 15591624.
41. Global Polio Eradication Initiative. Funding update. Annual expenditures and forecasts 1988–20082007. http://www.polioeradication.org/content/general/FRR_07Jan_AnnualExpenditure.pdf.
42. Steverding D, The history of African trypanosomiasis. Parasit Vectors. 2008;1(1):3. doi: 10.1186/1756-3305-1-3 18275594.
43. Najera JA, Gonzalez-Silva M, Alonso PL, Some lessons for the future from the Global Malaria Eradication Programme (1955–1969). PLoS Med. 2011;8(1):e1000412. doi: 10.1371/journal.pmed.1000412 21311585.
44. Tiben DDHaDER. Q&A on the historic Guinea worm eradication campaign. The Carter Center.
45. Kastner RJ, Stone CM, Steinmann P, Tanner M, Tediosi F, What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs. PLoS neglected tropical diseases. 2015;9(10):e0004147. doi: 10.1371/journal.pntd.0004147 26451729.
46. Brady MA, Stelmach R, Davide-Smith M, Johnson J, Pou B, Koroma J, et al. Costs of Transmission Assessment Surveys to Provide Evidence for the Elimination of Lymphatic Filariasis. PLoS neglected tropical diseases. 2017;11(2):e0005097. doi: 10.1371/journal.pntd.0005097 28146557
47. Caldwell D, Briggs A, Sculpher M, Claxton K, Decision Modelling for Health Economic Evaluation. Int J Epidemiol. 2007;36(2):476–7. doi: 10.1093/ije/dym062
48. Baker MC, McFarland DA, Gonzales M, Diaz MJ, Molyneux DH, The impact of integrating the elimination programme for lymphatic filariasis into primary health care in the Dominican Republic. Int J Health Plann Manage. 2007;22(4):337–52. doi: 10.1002/hpm.900 17729213.
49. Baker MC, Mathieu E, Fleming FM, Deming M, King JD, Garba A, et al. Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework. Lancet. 2010;375(9710):231–8. doi: 10.1016/S0140-6736(09)61458-6 20109924.
50. Evans DS, Unnasch TR, Richards FO, Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time. Lancet. 2015;385(9983):2151–2. doi: 10.1016/S0140-6736(15)61022-4 26068266.
51. Stone CM, Lindsay SW, Chitnis N, How Effective is Integrated Vector Management Against Malaria and Lymphatic Filariasis Where the Diseases Are Transmitted by the Same Vector?PLoS Negl Trop Dis. 2014;8(12):e3393. doi: 10.1371/journal.pntd.0003393 25501002.
52. Sobti D, Cueto M, He Y, A public health achievement under adversity: the eradication of poliomyelitis from Peru, 1991. Am J Public Health. 2014;104(12):2298–305. doi: 10.2105/AJPH.2014.301995 25322297.
53. Rebollo MP, Mohammed KA, Thomas B, Ame S, Ali SM, Cano J, et al. Cessation of mass drug administration for lymphatic filariasis in Zanzibar in 2006: was transmission interrupted?PLoS Negl Trop Dis. 2015;9(3):e0003669. doi: 10.1371/journal.pntd.0003669 25816287.
54. Bockarie MJ, Pedersen EM, White GB, Michael E, Role of vector control in the global program to eliminate lymphatic filariasis. Annu Rev Entomol. 2009;54:469–87. doi: 10.1146/annurev.ento.54.110807.090626 18798707.
55. Evans D, McFarland D, Adamani W, Eigege A, Miri E, Schulz J, et al. Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria. Ann Trop Med Parasitol. 2011;105(8):537–47. doi: 10.1179/2047773211Y.0000000010 22325813.
56. McLaughlin SI, Radday J, Michel MC, Addiss DG, Beach MJ, Lammie PJ, et al. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. Am J Trop Med Hyg. 2003;68(5):568–73. 12812348.
57. Damian G R R. Guidelines for Preparing an Eradication Investment Case. Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, MA: Strüngmann Forum Report. p. 149–56.
58. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA, The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). PLoS Negl Trop Dis. 2010;4(6):e708. doi: 10.1371/journal.pntd.0000708 20532228.